CRL
Charles River Laboratories International, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum-inputs (vergelijkbare managers): breedte van houders 0.0% · aandelenstroom -0.9% · netto nieuwe posities 0.0% — formule
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q1 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q2 2026 | 140 | -1 | 45.53M | $10.31B | +6 | −6 |
| Q1 2026 | 143 | -7 | 45.52M | $7.86B | +6 | −14 |
| Q4 2025 | 150 | +3 | 43.69M | $8.72B | +4 | — |
| Q3 2025 | 22 | 0 | 23.18M | $3.62B | +1 | −2 |
| Q2 2025 | 20 | +2 | 21.36M | $3.24B | +4 | −2 |
| Q1 2025 | 15 | 0 | 9.57M | $1.44B | +1 | −1 |
| Q4 2024 | 15 | +1 | 9.65M | $1.78B | +1 | — |
| Q3 2024 | 13 | -1 | 6.67M | $1.31B | — | −1 |
| Q2 2024 | 14 | — | 3.92M | $810.09M | — | — |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 2 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 3 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 4 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 5 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 7 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 4.29M | +5.1% | $644.98M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 9 | State Street Global Advisors ✦ (passief) | 1.90M | -12.8% | $286.38M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 10 | Geode Capital Management ✦ (passief) | 1.26M | +2.5% | $189.94M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Geode Capital Management ✦ (passief) | 1.26M | +2.5% | $189.94M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Norges Bank ✦ (passief) | 437.81K | -18.3% | $65.90M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Arrowstreet Capital ✦ | 353.58K | Nieuw | $53.22M | 0.0% | New | 1 | SEC ↗ |
| 14 | Citadel Advisors ✦ | 282.02K | +65.3% | $42.45M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 282.02K | +65.3% | $42.45M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 16 | PRIMECAP Management ✦ | 272.89K | 0.0% | $41.08M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 255.22K | +9.9% | $38.42M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 163.34K | +107.1% | $24.59M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 154.78K | +25.1% | $23.30M | 0.2% | ▲ Add | 4 | SEC ↗ |
| 20 | T. Rowe Price ✦ | 75.97K | -55.6% | $11.44M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 21 | Millennium Management ✦ | 74.50K | -80.0% | $11.21M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 22 | Marshall Wace ✦ | 37.93K | +75.6% | $5.71M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 23 | Marshall Wace ✦ | 37.93K | +75.6% | $5.71M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 24 | Marshall Wace ✦ | 37.93K | +75.6% | $5.71M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 25 | AQR Capital Management ✦ | 6.24K | -70.3% | $930,224 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 26 | AQR Capital Management ✦ | 6.24K | -70.3% | $930,224 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 27 | AQR Capital Management ✦ | 6.24K | -70.3% | $930,224 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 28 | AQR Capital Management ✦ | 6.24K | -70.3% | $930,224 | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 29 | Baillie Gifford ✦ | 49 | -99.9% | $7,375 | 0.0% | ▼ Trim | 4 | SEC ↗ |
"Hun gewicht" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die beheerder — de overtuigingsmaatstaf. ✦ = gecureerde beheerder.
Nieuwe kopers
| Arrowstreet Capital | $53.22M | 0.0% |
Verlaten
| D. E. Shaw & Co. | $15.63M | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 555 houders, 56.84M aandelen, $9.32B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect verder het vaakst bezitten — aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 2.04K aand · $599,711
Director · 573 aand · $163,443
Officer · 3.71K aand · $1.04M
Officer, Director · 6.50K aand · $1.82M
Director · 28.73K aand · $7.90M
Officer · 404 aand · $104,446
Officer · 1.21K aand · $311,529
Officer · 736 aand · $190,278
Officer · 4.18K aand · $1.08M
Officer · 1.27K aand · $330,055
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie